RTI-229 is an investigational medication related to the treatment of certain neurodegenerative diseases, specifically targeting conditions like Alzheimer's disease. It is a small molecule that is designed to interfere with the aggregation of amyloid-beta peptides, which are believed to play a significant role in the pathogenesis of Alzheimer’s disease. By potentially preventing or reducing this aggregation, RTI-229 may help alleviate some of the cognitive decline associated with Alzheimer's.
New to topics? Read the docs here!